Excessive Sleepiness
Conditions
Brief summary
The primary objective of the study is to determine whether armodafinil treatment is more effective than placebo treatment in patients with excessive sleepiness associated with shift work disorder (SWD) by measuring improved clinical condition late in the shift, including the commute home.
Interventions
DRUGArmodafinil
At the baseline visit, patients who continued to meet eligibility criteria were randomly assigned (1:1) to receive either 150 mg of armodafinil or matching placebo treatment only on nights worked for 6 weeks. Study drug was taken once nightly, 30 to 60 minutes prior to the start of the night shift, on nights worked. Armodafinil treatment was titrated as follows (only on nights worked): the first dose was 50 mg (1 tablet), the second and third doses were 100 mg (2 tablets), and the fourth and subsequent doses were 150 mg (3 tablets). Placebo tablets matching armodafinil tablets were administered on the same schedule.
DRUGMatching Placebo
At the baseline visit, patients who continued to meet eligibility criteria were randomly assigned (1:1) to receive either 150 mg of armodafinil or matching placebo treatment only on nights worked for 6 weeks. Study drug was taken once nightly, 30 to 60 minutes prior to the start of the night shift, on nights worked. Armodafinil treatment was titrated as follows (only on nights worked): the first dose was 50 mg (1 tablet), the second and third doses were 100 mg (2 tablets), and the fourth and subsequent doses were 150 mg (3 tablets). Placebo tablets matching armodafinil tablets were administered on the same schedule.
Sponsors
Cephalon
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. The patient currently meets the criteria for Shift Work Disorder (SWD) for duration of at least 1 month. 2. The patient has the presence of excessive sleepiness late in the shift, including the commute home if applicable, with a Clinical Global Impression of Severity of Illness (CGI-S) rating of 4 or more at screening. 3. The patient has clinically significant difficulty in social or occupational functioning, with a Global Assessment of Function (GAF) score less than 70 (on clinician interview) at screening. 4. The patient has a Karolinska Sleepiness Scale (KSS) score of 6 or more at screening (visit 1) that is confirmed at baseline (visit 2). 5. The patient works at least 5 night shifts per month, of which at least 3 nights are consecutive, and plans to maintain this schedule. 6. The patient works night shifts or rotating shifts that include at least 6 hours between 2200 and 0800 (including the time period 0400 to 0800), and shifts are no longer than 12 hours in duration. 7. The patient is in good health, as judged by the investigator. 8. The patient is able to complete self-rating scales. 9. Women of childbearing potential (not surgically sterile or 2 years postmenopausal), must use a medically accepted method of contraception, and must continue use of 1 of these methods for the duration of the study (and for 30 days after participation in the study). Acceptable methods of contraception include: abstinence, barrier method with spermicide, steroidal contraceptive (oral, transdermal, implanted, and injected) in conjunction with a barrier method, or intrauterine device (IUD). 10. The patient is willing and able to comply with study restrictions and to attend regularly scheduled clinic visits as specified in this protocol
Exclusion criteria
1. The patient has mild or more severe obstructive sleep apnea (OSA) defined as an apnea/hypopnea index more than 5 as determined by daytime polysomnography (PSG). 2. The patient has a medical or psychiatric disorder causing clinically significant functional impairment or contributing to the patient's excessive sleepiness. 3. The patient is currently taking a medication or substance that is causing clinically significant functional impairment or contributing to the patient's excessive sleepiness. 4. The patient has a clinically significant treated or untreated medical condition. 5. The patient has a history of clinically significant suicidal ideation in the judgment of the principal investigator or is currently suicidal based on medical and psychiatric history. 6. The patient has a known hypersensitivity to armodafinil, racemic modafinil, or any component of the study drug tablets. 7. The patient has a history of any clinically significant cutaneous drug reaction, or a history of clinically significant hypersensitivity reaction, including multiple allergies or drug reactions. 8. The patient consumes caffeine including coffee, tea and/or other caffeine containing beverages or food averaging more than 600 mg of caffeine per day within 7 days of the baseline visit. 9. The patient uses any prescription or over-the-counter (OTC) drugs disallowed by the protocol within 30 days of the baseline visit. 10. The patient has been in a prior armodafinil study. 11. The patient has a history of alcohol, narcotic, or any other drug abuse. 12. The patient has a positive urine drug screen (UDS) without medical explanation at the screening visit. 13. The patient has a clinically significant deviation from normal on physical examination. 14. The patient is a pregnant or lactating woman. 15. The patient has used an investigational drug within 1 month of the screening visit. 16. The patient has a disorder that could interfere with the absorption, distribution, metabolism, or excretion of the investigational product. 17. The patient needs to use any of the excluded medications in this protocol.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Patients With at Least Minimal Improvement From Baseline in the Clinical Global Impression of Change (CGI-C) Rating as Related to Late Shift Sleepiness at Endpoint | Baseline and week 6 (or last observation after baseline) | The Clinical Global Impression of Change (CGI-C) is an assessment performed by the clinician, evaluating the change in the patient's symptoms over time. The clinician categorizes the change as: very much improved, much improved, minimally improved, no change, minimally worse, much worse, or very much worse. The data presented here represents the percentage of patients whose condition showed at least minimal improvement in the CGI-C rating as related to late shift sleepiness (defined as the period 0400-0800, including the commute home). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline to Week 3 in Global Assessment of Functioning | Baseline and Week 3 | The Global Assessment of Functioning (GAF) is a numeric scale (0 through 100) used by the clinician to rate the social, occupational, and psychological functioning of the patient. A higher score indicates superior functioning and fewer symptoms. The data presented here represents the mean change from baseline in the GAF scores of each group. |
| Change From Baseline to Week 6 in Global Assessment of Functioning | Baseline and Week 6 | The Global Assessment of Functioning (GAF) is a numeric scale (0 through 100) used by the clinician to rate the social, occupational, and psychological functioning of the patient. A higher score indicates superior functioning and fewer symptoms. The data presented here represents the mean change from baseline in the GAF scores of each group. |
| Change From Baseline to Endpoint in the Mean Karolinska Sleepiness Scale (KSS) Score | Baseline and week 6 (or last observation after baseline) | The Karolinska sleepiness scale is a 10-point scale, on which the participant has to mark his sleepiness during the previous 10 minutes. The scale ranges from 1, which indicates extremely alert, to 10, which indicates extremely sleepy, can't stay awake. The KSS was performed by the participant at the baseline visit, week 3, and week 6 (or early termination visit). The score recorded is the average of 3 assessments within ±15 minutes at 0400, 0600, and 0800. The data presented here represents the mean change from baseline in the KSS scores of each group. |
| Change From Baseline to Week 3 in the Mean Karolinska Sleepiness Scale (KSS) Score | Baseline and week 3 | The Karolinska sleepiness scale is a 10-point scale, on which the participant has to mark his sleepiness during the previous 10 minutes. The scale ranges from 1, which indicates extremely alert, to 10, which indicates extremely sleepy, can't stay awake. The KSS was performed by the participant at the baseline visit, week 3, and week 6 (or early termination visit). The score recorded is the average of 3 assessments within ±15 minutes at 0400, 0600, and 0800. The data presented here represents the mean change from baseline in the KSS scores of each group. |
| Change From Baseline to Week 6 in the Mean Karolinska Sleepiness Scale (KSS) Score | Baseline and week 6 | The Karolinska sleepiness scale is a 10-point scale, on which the participant has to mark his sleepiness during the previous 10 minutes. The scale ranges from 1, which indicates extremely alert, to 10, which indicates extremely sleepy, can't stay awake. The KSS was performed by the participant at the baseline visit, week 3, and week 6 (or early termination visit). The score recorded is the average of 3 assessments within ±15 minutes at 0400, 0600, and 0800. The data presented here represents the mean change from baseline in the KSS scores of each group. |
| Percentage of Patients With at Least Minimal Improvement From Baseline in the Clinical Global Impression of Change (CGI-C) Rating as Related to Late Shift Sleepiness at Week 3 | Baseline and week 3 | The Clinical Global Impression of Change (CGI-C) is an assessment performed by the clinician, evaluating the change in the patient's symptoms over time. The clinician categorizes the change as: very much improved, much improved, minimally improved, no change, minimally worse, much worse, or very much worse. The data presented here represents the percentage of patients whose condition showed at least minimal improvement in the CGI-C rating as related to late shift sleepiness (defined as the period 0400-0800, including the commute home). |
| Percentage of Patients With at Least Minimal Improvement From Baseline in the Clinical Global Impression of Change (CGI-C) Rating as Related to Late Shift Sleepiness at Week 6 | Baseline and week 6 | The Clinical Global Impression of Change (CGI-C) is an assessment performed by the clinician, evaluating the change in the patient's symptoms over time. The clinician categorizes the change as: very much improved, much improved, minimally improved, no change, minimally worse, much worse, or very much worse. The data presented here represents the percentage of patients whose condition showed at least minimal improvement in the CGI-C rating as related to late shift sleepiness (defined as the period 0400-0800, including the commute home). |
| Change From Baseline to Endpoint in the Modified Sheehan Disability Scale (MSDS) Composite Score | Baseline and week 6 (or last observation after baseline) | Mental-health related disability was assessed with the Modified Sheehan Disability Scale (MSDS). The MSDS has three 11-point items, and the participant is asked to rate, on a numerical scale, the extent to which emotional problems have disrupted her/his work, social life, and family life/home responsibilities over the last month. Each item is rated from 0, indicating not at all, to 10, indicating extremely. Scores for the items are summed for a possible score of 0 to 30. The MSDS was performed by the patient at the baseline visit, at Week 3, and at Week 6. |
| Change From Baseline to Endpoint in the Modified Sheehan Disability Scale (MSDS) Work Item Score | Baseline and week 6 (or last observation after baseline) | Mental-health related disability was assessed with the Modified Sheehan Disability Scale (MSDS). The MSDS has three 11-point items, and the participant is asked to rate, on a numerical scale, the extent to which emotional problems have disrupted her/his work, social life, and family life/home responsibilities over the last month. Each item is rated from 0, indicating not at all, to 10, indicating extremely. Scores for the items are summed for a possible score of 0 to 30. The MSDS was performed by the patient at the baseline visit, at Week 3, and at Week 6. |
| Change From Baseline to Endpoint in the Modified Sheehan Disability Scale (MSDS) Social Life Item Score | Baseline and week 6 (or last observation (or last observation after baseline)) | Mental-health related disability was assessed with the Modified Sheehan Disability Scale (MSDS). The MSDS has three 11-point items, and the participant is asked to rate, on a numerical scale, the extent to which emotional problems have disrupted her/his work, social life, and family life/home responsibilities over the last month. Each item is rated from 0, indicating not at all, to 10, indicating extremely. Scores for the items are summed for a possible score of 0 to 30. The MSDS was performed by the patient at the baseline visit, at Week 3, and at Week 6. |
| Change From Baseline to Endpoint in the Modified Sheehan Disability Scale (MSDS) Family Life Item Score | Baseline and week 6 (or last observation after baseline) | Mental-health related disability was assessed with the Modified Sheehan Disability Scale (MSDS). The MSDS has three 11-point items, and the participant is asked to rate, on a numerical scale, the extent to which emotional problems have disrupted her/his work, social life, and family life/home responsibilities over the last month. Each item is rated from 0, indicating not at all, to 10, indicating extremely. Scores for the items are summed for a possible score of 0 to 30. The MSDS was performed by the patient at the baseline visit, at Week 3, and at Week 6. |
| Change From Baseline to Endpoint in Global Assessment of Function (GAF) Score | Baseline and week 6 (or last observation after baseline) | The Global Assessment of Functioning (GAF) is a numeric scale (0 through 100) used by the clinician to rate the social, occupational, and psychological functioning of the patient. A higher score indicates superior functioning and fewer symptoms. The data presented here represents the mean change from baseline to endpoint in the GAF scores of each group. |
| Change From Baseline to Endpoint in the Modified Sheehan Disability Scale (MSDS) Score - Number of Days of Reduced Productivity | Baseline and week 6 (or last observation after baseline) | Mental-health related disability was assessed with the Modified Sheehan Disability Scale (MSDS). The MSDS has three 11-point items, and the participant is asked to rate, on a numerical scale, the extent to which emotional problems have disrupted her/his work, social life, and family life/home responsibilities over the last month. Each item is rated from 0, indicating not at all, to 10, indicating extremely. Scores for the items are summed for a possible score of 0 to 30. The MSDS was performed by the patient at the baseline visit, at Week 3, and at Week 6. |
| Treatment Satisfaction Questionnaire for Medication (TSQM)- Effectiveness Score at Endpoint | Endpoint | TSQM is a 14 question questionnaire assessing satisfaction with the medication. 4 scales are generated: side effects, effectiveness, convenience, and global satisfaction. Subjects responded to the questionnaire at Week 3, Week 6, and last observation after baseline. Optional responses are: Extremely Dissatisfied, Very Dissatisfied, Dissatisfied, Somewhat Satisfied, Satisfied, Very Satisfied, and Extremely Satisfied. From the responses, a scale score from 0 - 100 is calculated, with a higher score indicating greater satisfaction. Results from the Effectiveness scale are presented here. |
| Treatment Satisfaction Questionnaire for Medication (TSQM)- Side Effects Score at Endpoint | Endpoint | TSQM is a 14 question questionnaire assessing satisfaction with the medication. 4 scales are generated: side effects, effectiveness, convenience, and global satisfaction. Subjects responded to the questionnaire at Week 3, Week 6, and last post-baseline observation. Optional responses are: Extremely Dissatisfied, Very Dissatisfied, Dissatisfied, Somewhat Satisfied, Satisfied, Very Satisfied, and Extremely Satisfied. From the responses, a scale score from 0 - 100 is calculated, with a higher score indicating greater satisfaction. Results from the Side Effects scale are presented here. |
| Treatment Satisfaction Questionnaire for Medication (TSQM)- Convenience Score at Endpoint | Endpoint | TSQM is a 14 question questionnaire assessing satisfaction with the medication. 4 scales are generated: side effects, effectiveness, convenience, and global satisfaction. Subjects responded to the questionnaire at Week 3, Week 6, and last observation after baseline. Optional responses are: Extremely Dissatisfied, Very Dissatisfied, Dissatisfied, Somewhat Satisfied, Satisfied, Very Satisfied, and Extremely Satisfied. From the responses, a scale score from 0 - 100 is calculated, with a higher score indicating greater satisfaction. Results from the Convenience scale are presented here. |
| Treatment Satisfaction Questionnaire for Medication (TSQM)- Global Satisfaction Score at Endpoint | Endpoint | TSQM is a 14 question questionnaire assessing satisfaction with the medication. 4 scales are generated: side effects, effectiveness, convenience, and global satisfaction. Subjects responded to the questionnaire at Week 3, Week 6, and last observation after baseline. Optional responses are: Extremely Dissatisfied, Very Dissatisfied, Dissatisfied, Somewhat Satisfied, Satisfied, Very Satisfied, and Extremely Satisfied. From the responses, a scale score from 0 - 100 is calculated, with a higher score indicating greater satisfaction. Results from the Global Satisfaction scale are presented here. |
| Change From Baseline to Endpoint in the Functional Outcomes of Sleep Questionnaire (FOSQ-10) Total Score | Baseline and week 6 (or last observation after baseline) | FOSQ-10 consists of 10 questions, on a scale of 1-4(1=extreme difficulty 4=no difficulty), measures impact of sleepiness on activities of daily living. Lower score = more difficulty with activity due to lack of sleep. Total score = MEAN of subscale scores (vigilance, productivity, social outcome, intimacy, activity) multiplied by 5. Worst total score is 5 (maximum difficulty) the best is 20 (no difficulty). This data reports CHANGE in total score from baseline to endpoint, with higher (positive) values representing improvement. Worst possible CHANGE value would be -15 best would be +15. |
| Change From Baseline to Endpoint in the Functional Outcomes of Sleep Questionnaire (FOSQ-10) Activity Level Score | Baseline and week 6 (or last observation after baseline) | FOSQ-10 consists of 10 questions rated on a scale of 1 to 4 (1=extreme difficulty and 4=no difficulty), and is used to measure the impact of daytime sleepiness on activities of daily living and quality of life. A total score and 5 subscale (vigilance, general productivity, social outcome, intimacy, and activity level) scores are calculated from the responses. Worst subscale score is 1 (maximum difficulty) and the best score is 4 (no difficulty). This score represents the CHANGE from Baseline in the Activity level subscale. Positive change scores represent improvement (possible range -3 to +3). |
| Change From Baseline to Endpoint in the Functional Outcomes of Sleep Questionnaire (FOSQ-10) General Productivity Score | Baseline and week 6 (or last observation after baseline) | FOSQ-10 consists of 10 questions rated on a scale of 1-4 (1=extreme difficulty, 4=no difficulty), and is used to measure the impact of daytime sleepiness on activities of daily living and quality of life. A total score and 5 subscale (vigilance, general productivity, social outcome, intimacy, and activity level) scores are calculated from the responses. Worst subscale score is 1 (maximum difficulty) and the best score is 4 (no difficulty). This score represents the CHANGE from Baseline in the General Productivity subscale. Positive change scores represent improvement (possible range -3 to +3). |
| Change From Baseline to Endpoint in the Functional Outcomes of Sleep Questionnaire (FOSQ-10) Vigilance Score | Baseline and week 6 (or last observation after baseline) | FOSQ-10 consists of 10 questions rated on a scale of 1-4 (1=extreme difficulty, 4=no difficulty), and is used to measure the impact of daytime sleepiness on activities of daily living and quality of life. A total score and 5 subscale (vigilance, general productivity, social outcome, intimacy, and activity level) scores are calculated from the responses. Worst subscale score is 1 (maximum difficulty) and the best score is 4 (no difficulty). This score represents the CHANGE from Baseline in the Vigilance subscale. Positive change scores represent improvement (possible range -3 to +3). |
| Change From Baseline to Endpoint in the Functional Outcomes of Sleep Questionnaire (FOSQ-10) Social Outcome | Baseline and week 6 (or last observation after baseline) | FOSQ-10 consists of 10 questions rated on a scale of 1-4 (1=extreme difficulty, 4=no difficulty), and is used to measure the impact of daytime sleepiness on activities of daily living and quality of life. A total score and 5 subscale (vigilance, general productivity, social outcome, intimacy, and activity level) scores are calculated from the responses. Worst subscale score is 1 (maximum difficulty) and the best score is 4 (no difficulty). This score represents the CHANGE from Baseline in the Social Outcome subscale. Positive change scores represent improvement (possible range -3 to +3). |
| Change From Baseline to Endpoint in the Functional Outcomes of Sleep Questionnaire (FOSQ-10) Intimacy | Baseline and week 6 (or last observation after baseline) | FOSQ-10 consists of 10 questions rated on a scale of 1-4 (1=extreme difficulty, 4=no difficulty), and is used to measure the impact of daytime sleepiness on activities of daily living and quality of life. A total score and 5 subscale (vigilance, general productivity, social outcome, intimacy, and activity level) scores are calculated from the responses. Worst subscale score is 1 (maximum difficulty) and the best score is 4 (no difficulty). This score represents the CHANGE from Baseline in the Intimacy subscale. Positive change scores represent improvement (possible range -3 to +3). |
| Change From Baseline to Endpoint in the Modified Sheehan Disability Scale (MSDS) Score - Days Missed Work or Unable to Carry Out Responsibilities | Baseline and week 6 (or last observation after baseline) | Mental-health related disability was assessed with the Modified Sheehan Disability Scale (MSDS). The MSDS has three 11-point items, and the participant is asked to rate, on a numerical scale, the extent to which emotional problems have disrupted her/his work, social life, and family life/home responsibilities over the last month. Each item is rated from 0, indicating not at all, to 10, indicating extremely. Scores for the items are summed for a possible score of 0 to 30. The MSDS was performed by the patient at the baseline visit, at Week 3, and at Week 6. |
Countries
United States
Participant flow
Recruitment details
385 patients at 45 centers in the US met entry criteria and were considered eligible for enrollment into the study; 2 of these patients enrolled twice under different identification numbers. Of the 383 patients enrolled, 371 received at least 1 dose of study drug and were evaluated for safety; 12 patients withdrew before taking any study drug.
Pre-assignment details
The study consisted of a 1- to 3-week screening period, a 1-week baseline period (followed by randomization), and a 6-week double-blind treatment period.
Participants by arm
| Arm | Count |
|---|---|
| 150 mg/Day Armodafinil At the baseline visit, patients who continued to meet eligibility criteria were randomly assigned (1:1) to receive either 150 mg of armodafinil or matching placebo treatment only on nights worked for 6 weeks. Study drug was taken once nightly, 30 to 60 minutes prior to the start of the night shift, on nights worked. Armodafinil treatment was titrated as follows (only on nights worked): the first dose was 50 mg (1 tablet), the second and third doses were 100 mg (2 tablets), and the fourth and subsequent doses were 150 mg (3 tablets). Placebo tablets matching armodafinil tablets were administered on the same schedule. | 193 |
| Matching Placebo At the baseline visit, patients who continued to meet eligibility criteria were randomly assigned (1:1) to receive either 150 mg of armodafinil or matching placebo treatment only on nights worked for 6 weeks. Study drug was taken once nightly, 30 to 60 minutes prior to the start of the night shift, on nights worked. Armodafinil treatment was titrated as follows (only on nights worked): the first dose was 50 mg (1 tablet), the second and third doses were 100 mg (2 tablets), and the fourth and subsequent doses were 150 mg (3 tablets). Placebo tablets matching armodafinil tablets were administered on the same schedule. | 190 |
| Total | 383 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Adverse Event | 9 | 1 |
| Overall Study | Began working day shift | 0 | 2 |
| Overall Study | Lack of Efficacy | 0 | 1 |
| Overall Study | Laid off or terminated from job | 1 | 2 |
| Overall Study | Lost to Follow-up | 6 | 4 |
| Overall Study | Moved away without notifying center | 1 | 0 |
| Overall Study | Noncompliance to study procedures | 1 | 1 |
| Overall Study | Noncompliance with drug administration | 1 | 1 |
| Overall Study | Protocol Violation | 7 | 6 |
| Overall Study | Stopped working consistent night shifts | 0 | 1 |
| Overall Study | Switched to first shift | 1 | 0 |
| Overall Study | Withdrawal by Subject | 7 | 2 |
| Overall Study | Work schedule and travel | 0 | 1 |
| Overall Study | Work schedule changing | 1 | 1 |
Baseline characteristics
| Characteristic | Matching Placebo | 150 mg/Day Armodafinil | Total |
|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical Between 18 and 65 years | 190 Participants | 193 Participants | 383 Participants |
| Age Continuous | 36.1 years STANDARD_DEVIATION 10.75 | 36.7 years STANDARD_DEVIATION 10.71 | 36.4 years STANDARD_DEVIATION 10.72 |
| Region of Enrollment United States | 190 participants | 193 participants | 383 participants |
| Sex: Female, Male Female | 90 Participants | 85 Participants | 175 Participants |
| Sex: Female, Male Male | 100 Participants | 108 Participants | 208 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 55 / 184 | 22 / 187 |
| serious Total, serious adverse events | 0 / 184 | 1 / 187 |
Outcome results
Primary
Percentage of Patients With at Least Minimal Improvement From Baseline in the Clinical Global Impression of Change (CGI-C) Rating as Related to Late Shift Sleepiness at Endpoint
The Clinical Global Impression of Change (CGI-C) is an assessment performed by the clinician, evaluating the change in the patient's symptoms over time. The clinician categorizes the change as: very much improved, much improved, minimally improved, no change, minimally worse, much worse, or very much worse. The data presented here represents the percentage of patients whose condition showed at least minimal improvement in the CGI-C rating as related to late shift sleepiness (defined as the period 0400-0800, including the commute home).
Time frame: Baseline and week 6 (or last observation after baseline)
Population: The number of participants analyzed represents the number of participants with evaluable data.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| 150 mg/Day Armodafinil | Percentage of Patients With at Least Minimal Improvement From Baseline in the Clinical Global Impression of Change (CGI-C) Rating as Related to Late Shift Sleepiness at Endpoint | 77 Percentage of participants |
| Matching Placebo | Percentage of Patients With at Least Minimal Improvement From Baseline in the Clinical Global Impression of Change (CGI-C) Rating as Related to Late Shift Sleepiness at Endpoint | 57 Percentage of participants |
Secondary
Change From Baseline to Endpoint in Global Assessment of Function (GAF) Score
The Global Assessment of Functioning (GAF) is a numeric scale (0 through 100) used by the clinician to rate the social, occupational, and psychological functioning of the patient. A higher score indicates superior functioning and fewer symptoms. The data presented here represents the mean change from baseline to endpoint in the GAF scores of each group.
Time frame: Baseline and week 6 (or last observation after baseline)
Population: The number of participants analyzed represents the number of participants with evaluable data.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| 150 mg/Day Armodafinil | Change From Baseline to Endpoint in Global Assessment of Function (GAF) Score | 9.4 Units on a scale | Standard Error 0.62 |
| Matching Placebo | Change From Baseline to Endpoint in Global Assessment of Function (GAF) Score | 5.0 Units on a scale | Standard Error 0.64 |
Secondary
Change From Baseline to Endpoint in the Functional Outcomes of Sleep Questionnaire (FOSQ-10) Activity Level Score
FOSQ-10 consists of 10 questions rated on a scale of 1 to 4 (1=extreme difficulty and 4=no difficulty), and is used to measure the impact of daytime sleepiness on activities of daily living and quality of life. A total score and 5 subscale (vigilance, general productivity, social outcome, intimacy, and activity level) scores are calculated from the responses. Worst subscale score is 1 (maximum difficulty) and the best score is 4 (no difficulty). This score represents the CHANGE from Baseline in the Activity level subscale. Positive change scores represent improvement (possible range -3 to +3).
Time frame: Baseline and week 6 (or last observation after baseline)
Population: Full analysis set defined as subjects who were assessed with FOSQ-10 at baseline and at endpoint
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| 150 mg/Day Armodafinil | Change From Baseline to Endpoint in the Functional Outcomes of Sleep Questionnaire (FOSQ-10) Activity Level Score | 0.7 Units on a scale | Standard Error 0.07 |
| Matching Placebo | Change From Baseline to Endpoint in the Functional Outcomes of Sleep Questionnaire (FOSQ-10) Activity Level Score | 0.5 Units on a scale | Standard Error 0.07 |
Secondary
Change From Baseline to Endpoint in the Functional Outcomes of Sleep Questionnaire (FOSQ-10) General Productivity Score
FOSQ-10 consists of 10 questions rated on a scale of 1-4 (1=extreme difficulty, 4=no difficulty), and is used to measure the impact of daytime sleepiness on activities of daily living and quality of life. A total score and 5 subscale (vigilance, general productivity, social outcome, intimacy, and activity level) scores are calculated from the responses. Worst subscale score is 1 (maximum difficulty) and the best score is 4 (no difficulty). This score represents the CHANGE from Baseline in the General Productivity subscale. Positive change scores represent improvement (possible range -3 to +3).
Time frame: Baseline and week 6 (or last observation after baseline)
Population: Full analysis set defined as subjects who were assessed with FOSQ-10 at baseline and at endpoint
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| 150 mg/Day Armodafinil | Change From Baseline to Endpoint in the Functional Outcomes of Sleep Questionnaire (FOSQ-10) General Productivity Score | 0.7 Units on a scale | Standard Error 0.07 |
| Matching Placebo | Change From Baseline to Endpoint in the Functional Outcomes of Sleep Questionnaire (FOSQ-10) General Productivity Score | 0.6 Units on a scale | Standard Error 0.08 |
Secondary
Change From Baseline to Endpoint in the Functional Outcomes of Sleep Questionnaire (FOSQ-10) Intimacy
FOSQ-10 consists of 10 questions rated on a scale of 1-4 (1=extreme difficulty, 4=no difficulty), and is used to measure the impact of daytime sleepiness on activities of daily living and quality of life. A total score and 5 subscale (vigilance, general productivity, social outcome, intimacy, and activity level) scores are calculated from the responses. Worst subscale score is 1 (maximum difficulty) and the best score is 4 (no difficulty). This score represents the CHANGE from Baseline in the Intimacy subscale. Positive change scores represent improvement (possible range -3 to +3).
Time frame: Baseline and week 6 (or last observation after baseline)
Population: Full analysis set defined as subjects who were assessed with FOSQ-10 at baseline and at endpoint
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| 150 mg/Day Armodafinil | Change From Baseline to Endpoint in the Functional Outcomes of Sleep Questionnaire (FOSQ-10) Intimacy | 0.6 Units on a scale | Standard Error 0.08 |
| Matching Placebo | Change From Baseline to Endpoint in the Functional Outcomes of Sleep Questionnaire (FOSQ-10) Intimacy | 0.5 Units on a scale | Standard Error 0.08 |
Secondary
Change From Baseline to Endpoint in the Functional Outcomes of Sleep Questionnaire (FOSQ-10) Social Outcome
FOSQ-10 consists of 10 questions rated on a scale of 1-4 (1=extreme difficulty, 4=no difficulty), and is used to measure the impact of daytime sleepiness on activities of daily living and quality of life. A total score and 5 subscale (vigilance, general productivity, social outcome, intimacy, and activity level) scores are calculated from the responses. Worst subscale score is 1 (maximum difficulty) and the best score is 4 (no difficulty). This score represents the CHANGE from Baseline in the Social Outcome subscale. Positive change scores represent improvement (possible range -3 to +3).
Time frame: Baseline and week 6 (or last observation after baseline)
Population: Full analysis set defined as subjects who were assessed with FOSQ-10 at baseline and at endpoint
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| 150 mg/Day Armodafinil | Change From Baseline to Endpoint in the Functional Outcomes of Sleep Questionnaire (FOSQ-10) Social Outcome | 0.6 Units on a scale | Standard Error 0.09 |
| Matching Placebo | Change From Baseline to Endpoint in the Functional Outcomes of Sleep Questionnaire (FOSQ-10) Social Outcome | 0.5 Units on a scale | Standard Error 0.09 |
Secondary
Change From Baseline to Endpoint in the Functional Outcomes of Sleep Questionnaire (FOSQ-10) Total Score
FOSQ-10 consists of 10 questions, on a scale of 1-4(1=extreme difficulty 4=no difficulty), measures impact of sleepiness on activities of daily living. Lower score = more difficulty with activity due to lack of sleep. Total score = MEAN of subscale scores (vigilance, productivity, social outcome, intimacy, activity) multiplied by 5. Worst total score is 5 (maximum difficulty) the best is 20 (no difficulty). This data reports CHANGE in total score from baseline to endpoint, with higher (positive) values representing improvement. Worst possible CHANGE value would be -15 best would be +15.
Time frame: Baseline and week 6 (or last observation after baseline)
Population: Full analysis set defined as subjects who were assessed with FOSQ-10 at baseline and at endpoint
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| 150 mg/Day Armodafinil | Change From Baseline to Endpoint in the Functional Outcomes of Sleep Questionnaire (FOSQ-10) Total Score | 3.3 Units on a scale | Standard Error 0.3 |
| Matching Placebo | Change From Baseline to Endpoint in the Functional Outcomes of Sleep Questionnaire (FOSQ-10) Total Score | 2.6 Units on a scale | Standard Error 0.32 |
Secondary
Change From Baseline to Endpoint in the Functional Outcomes of Sleep Questionnaire (FOSQ-10) Vigilance Score
FOSQ-10 consists of 10 questions rated on a scale of 1-4 (1=extreme difficulty, 4=no difficulty), and is used to measure the impact of daytime sleepiness on activities of daily living and quality of life. A total score and 5 subscale (vigilance, general productivity, social outcome, intimacy, and activity level) scores are calculated from the responses. Worst subscale score is 1 (maximum difficulty) and the best score is 4 (no difficulty). This score represents the CHANGE from Baseline in the Vigilance subscale. Positive change scores represent improvement (possible range -3 to +3).
Time frame: Baseline and week 6 (or last observation after baseline)
Population: Full analysis set defined as subjects who were assessed with FOSQ-10 at baseline and at endpoint
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| 150 mg/Day Armodafinil | Change From Baseline to Endpoint in the Functional Outcomes of Sleep Questionnaire (FOSQ-10) Vigilance Score | 0.7 Units on a scale | Standard Error 0.07 |
| Matching Placebo | Change From Baseline to Endpoint in the Functional Outcomes of Sleep Questionnaire (FOSQ-10) Vigilance Score | 0.5 Units on a scale | Standard Error 0.08 |
Secondary
Change From Baseline to Endpoint in the Mean Karolinska Sleepiness Scale (KSS) Score
The Karolinska sleepiness scale is a 10-point scale, on which the participant has to mark his sleepiness during the previous 10 minutes. The scale ranges from 1, which indicates extremely alert, to 10, which indicates extremely sleepy, can't stay awake. The KSS was performed by the participant at the baseline visit, week 3, and week 6 (or early termination visit). The score recorded is the average of 3 assessments within ±15 minutes at 0400, 0600, and 0800. The data presented here represents the mean change from baseline in the KSS scores of each group.
Time frame: Baseline and week 6 (or last observation after baseline)
Population: The number of participants analyzed represents the number of participants with evaluable data.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| 150 mg/Day Armodafinil | Change From Baseline to Endpoint in the Mean Karolinska Sleepiness Scale (KSS) Score | -2.8 Units on a scale | Standard Error 0.16 |
| Matching Placebo | Change From Baseline to Endpoint in the Mean Karolinska Sleepiness Scale (KSS) Score | -1.8 Units on a scale | Standard Error 0.17 |
Secondary
Change From Baseline to Endpoint in the Modified Sheehan Disability Scale (MSDS) Composite Score
Mental-health related disability was assessed with the Modified Sheehan Disability Scale (MSDS). The MSDS has three 11-point items, and the participant is asked to rate, on a numerical scale, the extent to which emotional problems have disrupted her/his work, social life, and family life/home responsibilities over the last month. Each item is rated from 0, indicating not at all, to 10, indicating extremely. Scores for the items are summed for a possible score of 0 to 30. The MSDS was performed by the patient at the baseline visit, at Week 3, and at Week 6.
Time frame: Baseline and week 6 (or last observation after baseline)
Population: Full analysis set defined as subjects who were assessed with MSDS at baseline and at Endpoint.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| 150 mg/Day Armodafinil | Change From Baseline to Endpoint in the Modified Sheehan Disability Scale (MSDS) Composite Score | -6.6 Units on a scale | Standard Error 0.6 |
| Matching Placebo | Change From Baseline to Endpoint in the Modified Sheehan Disability Scale (MSDS) Composite Score | -4.2 Units on a scale | Standard Error 0.62 |
Secondary
Change From Baseline to Endpoint in the Modified Sheehan Disability Scale (MSDS) Family Life Item Score
Mental-health related disability was assessed with the Modified Sheehan Disability Scale (MSDS). The MSDS has three 11-point items, and the participant is asked to rate, on a numerical scale, the extent to which emotional problems have disrupted her/his work, social life, and family life/home responsibilities over the last month. Each item is rated from 0, indicating not at all, to 10, indicating extremely. Scores for the items are summed for a possible score of 0 to 30. The MSDS was performed by the patient at the baseline visit, at Week 3, and at Week 6.
Time frame: Baseline and week 6 (or last observation after baseline)
Population: Full analysis set defined as subjects who were assessed with MSDS at baseline and at Endpoint.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| 150 mg/Day Armodafinil | Change From Baseline to Endpoint in the Modified Sheehan Disability Scale (MSDS) Family Life Item Score | -2.2 Units on a scale | Standard Error 0.23 |
| Matching Placebo | Change From Baseline to Endpoint in the Modified Sheehan Disability Scale (MSDS) Family Life Item Score | -1.5 Units on a scale | Standard Error 0.23 |
Secondary
Change From Baseline to Endpoint in the Modified Sheehan Disability Scale (MSDS) Score - Days Missed Work or Unable to Carry Out Responsibilities
Mental-health related disability was assessed with the Modified Sheehan Disability Scale (MSDS). The MSDS has three 11-point items, and the participant is asked to rate, on a numerical scale, the extent to which emotional problems have disrupted her/his work, social life, and family life/home responsibilities over the last month. Each item is rated from 0, indicating not at all, to 10, indicating extremely. Scores for the items are summed for a possible score of 0 to 30. The MSDS was performed by the patient at the baseline visit, at Week 3, and at Week 6.
Time frame: Baseline and week 6 (or last observation after baseline)
Population: Full analysis set defined as subjects who were assessed with MSDS at baseline and at Endpoint.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| 150 mg/Day Armodafinil | Change From Baseline to Endpoint in the Modified Sheehan Disability Scale (MSDS) Score - Days Missed Work or Unable to Carry Out Responsibilities | -0.5 Units on a scale | Standard Error 0.1 |
| Matching Placebo | Change From Baseline to Endpoint in the Modified Sheehan Disability Scale (MSDS) Score - Days Missed Work or Unable to Carry Out Responsibilities | -0.4 Units on a scale | Standard Error 0.1 |
Secondary
Change From Baseline to Endpoint in the Modified Sheehan Disability Scale (MSDS) Score - Number of Days of Reduced Productivity
Mental-health related disability was assessed with the Modified Sheehan Disability Scale (MSDS). The MSDS has three 11-point items, and the participant is asked to rate, on a numerical scale, the extent to which emotional problems have disrupted her/his work, social life, and family life/home responsibilities over the last month. Each item is rated from 0, indicating not at all, to 10, indicating extremely. Scores for the items are summed for a possible score of 0 to 30. The MSDS was performed by the patient at the baseline visit, at Week 3, and at Week 6.
Time frame: Baseline and week 6 (or last observation after baseline)
Population: Full analysis set defined as subjects who were assessed with MSDS at baseline and at Endpoint.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| 150 mg/Day Armodafinil | Change From Baseline to Endpoint in the Modified Sheehan Disability Scale (MSDS) Score - Number of Days of Reduced Productivity | -1.4 Units on a scale | Standard Error 0.13 |
| Matching Placebo | Change From Baseline to Endpoint in the Modified Sheehan Disability Scale (MSDS) Score - Number of Days of Reduced Productivity | -0.7 Units on a scale | Standard Error 0.14 |
Secondary
Change From Baseline to Endpoint in the Modified Sheehan Disability Scale (MSDS) Social Life Item Score
Mental-health related disability was assessed with the Modified Sheehan Disability Scale (MSDS). The MSDS has three 11-point items, and the participant is asked to rate, on a numerical scale, the extent to which emotional problems have disrupted her/his work, social life, and family life/home responsibilities over the last month. Each item is rated from 0, indicating not at all, to 10, indicating extremely. Scores for the items are summed for a possible score of 0 to 30. The MSDS was performed by the patient at the baseline visit, at Week 3, and at Week 6.
Time frame: Baseline and week 6 (or last observation (or last observation after baseline))
Population: Full analysis set defined as subjects who were assessed with MSDS at baseline and at Endpoint.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| 150 mg/Day Armodafinil | Change From Baseline to Endpoint in the Modified Sheehan Disability Scale (MSDS) Social Life Item Score | -2.2 Units on a scale | Standard Error 0.23 |
| Matching Placebo | Change From Baseline to Endpoint in the Modified Sheehan Disability Scale (MSDS) Social Life Item Score | -1.5 Units on a scale | Standard Error 0.24 |
Secondary
Change From Baseline to Endpoint in the Modified Sheehan Disability Scale (MSDS) Work Item Score
Mental-health related disability was assessed with the Modified Sheehan Disability Scale (MSDS). The MSDS has three 11-point items, and the participant is asked to rate, on a numerical scale, the extent to which emotional problems have disrupted her/his work, social life, and family life/home responsibilities over the last month. Each item is rated from 0, indicating not at all, to 10, indicating extremely. Scores for the items are summed for a possible score of 0 to 30. The MSDS was performed by the patient at the baseline visit, at Week 3, and at Week 6.
Time frame: Baseline and week 6 (or last observation after baseline)
Population: Full analysis set defined as subjects who were assessed with MSDS at baseline and at Endpoint.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| 150 mg/Day Armodafinil | Change From Baseline to Endpoint in the Modified Sheehan Disability Scale (MSDS) Work Item Score | -2.2 Units on a scale | Standard Error 0.24 |
| Matching Placebo | Change From Baseline to Endpoint in the Modified Sheehan Disability Scale (MSDS) Work Item Score | -1.2 Units on a scale | Standard Error 0.25 |
Secondary
Change From Baseline to Week 3 in Global Assessment of Functioning
The Global Assessment of Functioning (GAF) is a numeric scale (0 through 100) used by the clinician to rate the social, occupational, and psychological functioning of the patient. A higher score indicates superior functioning and fewer symptoms. The data presented here represents the mean change from baseline in the GAF scores of each group.
Time frame: Baseline and Week 3
Population: The number of participants analyzed represents the number of participants with evaluable data.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| 150 mg/Day Armodafinil | Change From Baseline to Week 3 in Global Assessment of Functioning | 6.9 Units on a scale | Standard Error 0.51 |
| Matching Placebo | Change From Baseline to Week 3 in Global Assessment of Functioning | 3.7 Units on a scale | Standard Error 0.52 |
Secondary
Change From Baseline to Week 3 in the Mean Karolinska Sleepiness Scale (KSS) Score
The Karolinska sleepiness scale is a 10-point scale, on which the participant has to mark his sleepiness during the previous 10 minutes. The scale ranges from 1, which indicates extremely alert, to 10, which indicates extremely sleepy, can't stay awake. The KSS was performed by the participant at the baseline visit, week 3, and week 6 (or early termination visit). The score recorded is the average of 3 assessments within ±15 minutes at 0400, 0600, and 0800. The data presented here represents the mean change from baseline in the KSS scores of each group.
Time frame: Baseline and week 3
Population: The number of participants analyzed represents the number of participants with evaluable data.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| 150 mg/Day Armodafinil | Change From Baseline to Week 3 in the Mean Karolinska Sleepiness Scale (KSS) Score | -2.6 Units on a scale | Standard Error 0.16 |
| Matching Placebo | Change From Baseline to Week 3 in the Mean Karolinska Sleepiness Scale (KSS) Score | -1.6 Units on a scale | Standard Error 0.16 |
Secondary
Change From Baseline to Week 6 in Global Assessment of Functioning
The Global Assessment of Functioning (GAF) is a numeric scale (0 through 100) used by the clinician to rate the social, occupational, and psychological functioning of the patient. A higher score indicates superior functioning and fewer symptoms. The data presented here represents the mean change from baseline in the GAF scores of each group.
Time frame: Baseline and Week 6
Population: The number of participants analyzed represents the number of participants with evaluable data.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| 150 mg/Day Armodafinil | Change From Baseline to Week 6 in Global Assessment of Functioning | 9.8 Units on a scale | Standard Error 0.66 |
| Matching Placebo | Change From Baseline to Week 6 in Global Assessment of Functioning | 4.9 Units on a scale | Standard Error 0.67 |
Secondary
Change From Baseline to Week 6 in the Mean Karolinska Sleepiness Scale (KSS) Score
The Karolinska sleepiness scale is a 10-point scale, on which the participant has to mark his sleepiness during the previous 10 minutes. The scale ranges from 1, which indicates extremely alert, to 10, which indicates extremely sleepy, can't stay awake. The KSS was performed by the participant at the baseline visit, week 3, and week 6 (or early termination visit). The score recorded is the average of 3 assessments within ±15 minutes at 0400, 0600, and 0800. The data presented here represents the mean change from baseline in the KSS scores of each group.
Time frame: Baseline and week 6
Population: The number of participants analyzed represents the number of participants with evaluable data.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| 150 mg/Day Armodafinil | Change From Baseline to Week 6 in the Mean Karolinska Sleepiness Scale (KSS) Score | -2.9 Units on a scale | Standard Error 0.17 |
| Matching Placebo | Change From Baseline to Week 6 in the Mean Karolinska Sleepiness Scale (KSS) Score | -1.8 Units on a scale | Standard Error 0.17 |
Secondary
Percentage of Patients With at Least Minimal Improvement From Baseline in the Clinical Global Impression of Change (CGI-C) Rating as Related to Late Shift Sleepiness at Week 3
The Clinical Global Impression of Change (CGI-C) is an assessment performed by the clinician, evaluating the change in the patient's symptoms over time. The clinician categorizes the change as: very much improved, much improved, minimally improved, no change, minimally worse, much worse, or very much worse. The data presented here represents the percentage of patients whose condition showed at least minimal improvement in the CGI-C rating as related to late shift sleepiness (defined as the period 0400-0800, including the commute home).
Time frame: Baseline and week 3
Population: Full analysis set defined as subjects who were assessed with CGI-C at baseline and at week 3
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| 150 mg/Day Armodafinil | Percentage of Patients With at Least Minimal Improvement From Baseline in the Clinical Global Impression of Change (CGI-C) Rating as Related to Late Shift Sleepiness at Week 3 | 78 Percentage of participants |
| Matching Placebo | Percentage of Patients With at Least Minimal Improvement From Baseline in the Clinical Global Impression of Change (CGI-C) Rating as Related to Late Shift Sleepiness at Week 3 | 51 Percentage of participants |
Secondary
Percentage of Patients With at Least Minimal Improvement From Baseline in the Clinical Global Impression of Change (CGI-C) Rating as Related to Late Shift Sleepiness at Week 6
The Clinical Global Impression of Change (CGI-C) is an assessment performed by the clinician, evaluating the change in the patient's symptoms over time. The clinician categorizes the change as: very much improved, much improved, minimally improved, no change, minimally worse, much worse, or very much worse. The data presented here represents the percentage of patients whose condition showed at least minimal improvement in the CGI-C rating as related to late shift sleepiness (defined as the period 0400-0800, including the commute home).
Time frame: Baseline and week 6
Population: Full analysis set defined as subjects who were assessed with CGI-C at baseline and at week 6
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| 150 mg/Day Armodafinil | Percentage of Patients With at Least Minimal Improvement From Baseline in the Clinical Global Impression of Change (CGI-C) Rating as Related to Late Shift Sleepiness at Week 6 | 80 Percentage of participants |
| Matching Placebo | Percentage of Patients With at Least Minimal Improvement From Baseline in the Clinical Global Impression of Change (CGI-C) Rating as Related to Late Shift Sleepiness at Week 6 | 56 Percentage of participants |
Secondary
Treatment Satisfaction Questionnaire for Medication (TSQM)- Convenience Score at Endpoint
TSQM is a 14 question questionnaire assessing satisfaction with the medication. 4 scales are generated: side effects, effectiveness, convenience, and global satisfaction. Subjects responded to the questionnaire at Week 3, Week 6, and last observation after baseline. Optional responses are: Extremely Dissatisfied, Very Dissatisfied, Dissatisfied, Somewhat Satisfied, Satisfied, Very Satisfied, and Extremely Satisfied. From the responses, a scale score from 0 - 100 is calculated, with a higher score indicating greater satisfaction. Results from the Convenience scale are presented here.
Time frame: Endpoint
Population: Full analysis set defined as subjects who completed the TSQM at Endpoint (Week 6 or last observation after baseline)
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| 150 mg/Day Armodafinil | Treatment Satisfaction Questionnaire for Medication (TSQM)- Convenience Score at Endpoint | 82.5 Units on a scale | Standard Error 1.5 |
| Matching Placebo | Treatment Satisfaction Questionnaire for Medication (TSQM)- Convenience Score at Endpoint | 80.7 Units on a scale | Standard Error 1.51 |
Secondary
Treatment Satisfaction Questionnaire for Medication (TSQM)- Effectiveness Score at Endpoint
TSQM is a 14 question questionnaire assessing satisfaction with the medication. 4 scales are generated: side effects, effectiveness, convenience, and global satisfaction. Subjects responded to the questionnaire at Week 3, Week 6, and last observation after baseline. Optional responses are: Extremely Dissatisfied, Very Dissatisfied, Dissatisfied, Somewhat Satisfied, Satisfied, Very Satisfied, and Extremely Satisfied. From the responses, a scale score from 0 - 100 is calculated, with a higher score indicating greater satisfaction. Results from the Effectiveness scale are presented here.
Time frame: Endpoint
Population: Full analysis set defined as subjects who completed the TSQM at Endpoint (Week 6 or last observation after baseline)
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| 150 mg/Day Armodafinil | Treatment Satisfaction Questionnaire for Medication (TSQM)- Effectiveness Score at Endpoint | 65.7 Units on a scale | Standard Error 2.46 |
| Matching Placebo | Treatment Satisfaction Questionnaire for Medication (TSQM)- Effectiveness Score at Endpoint | 46.1 Units on a scale | Standard Error 2.48 |
Secondary
Treatment Satisfaction Questionnaire for Medication (TSQM)- Global Satisfaction Score at Endpoint
TSQM is a 14 question questionnaire assessing satisfaction with the medication. 4 scales are generated: side effects, effectiveness, convenience, and global satisfaction. Subjects responded to the questionnaire at Week 3, Week 6, and last observation after baseline. Optional responses are: Extremely Dissatisfied, Very Dissatisfied, Dissatisfied, Somewhat Satisfied, Satisfied, Very Satisfied, and Extremely Satisfied. From the responses, a scale score from 0 - 100 is calculated, with a higher score indicating greater satisfaction. Results from the Global Satisfaction scale are presented here.
Time frame: Endpoint
Population: Full analysis set defined as subjects who completed the TSQM at Endpoint (Week 6 or last observation after baseline)
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| 150 mg/Day Armodafinil | Treatment Satisfaction Questionnaire for Medication (TSQM)- Global Satisfaction Score at Endpoint | 59.9 Units on a scale | Standard Error 2.72 |
| Matching Placebo | Treatment Satisfaction Questionnaire for Medication (TSQM)- Global Satisfaction Score at Endpoint | 44.1 Units on a scale | Standard Error 2.74 |
Secondary
Treatment Satisfaction Questionnaire for Medication (TSQM)- Side Effects Score at Endpoint
TSQM is a 14 question questionnaire assessing satisfaction with the medication. 4 scales are generated: side effects, effectiveness, convenience, and global satisfaction. Subjects responded to the questionnaire at Week 3, Week 6, and last post-baseline observation. Optional responses are: Extremely Dissatisfied, Very Dissatisfied, Dissatisfied, Somewhat Satisfied, Satisfied, Very Satisfied, and Extremely Satisfied. From the responses, a scale score from 0 - 100 is calculated, with a higher score indicating greater satisfaction. Results from the Side Effects scale are presented here.
Time frame: Endpoint
Population: Full analysis set defined as subjects who completed the TSQM at Endpoint (Week 6 or last observation after baseline)
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| 150 mg/Day Armodafinil | Treatment Satisfaction Questionnaire for Medication (TSQM)- Side Effects Score at Endpoint | 88.3 Units on a scale | Standard Error 1.62 |
| Matching Placebo | Treatment Satisfaction Questionnaire for Medication (TSQM)- Side Effects Score at Endpoint | 96.3 Units on a scale | Standard Error 1.63 |